Search

A patent has been issued for open-loop insulin delivery basal parameters based on insulin delivery records by Insulet Corporation. The device includes a processor, memory, wireless communication device, and artificial pancreas application to determine insulin delivery amounts and adjust basal dosages as needed. This technology aims to provide more accurate and personalized insulin delivery for individuals with Type 1 diabetes, addressing the challenges of manually determining optimal clinical parameters. The patent highlights the importance of updated open loop parameters for users utilizing automated insulin delivery systems. [Extracted from the article]

Researchers at Hamad Medical Corporation in Doha, Qatar, have conducted a study on Non-alcoholic Fatty Pancreas Disease (NAFPD), a condition characterized by lipid deposition in the pancreas. The study highlights the clinical associations, complications, diagnostic methods, and management of NAFPD, emphasizing the need for further research to fully understand its effects. This research provides valuable insights into the epidemiology and pathophysiology of NAFPD, aiming to enhance knowledge and awareness of this condition. [Extracted from the article]

A patent has been issued for a cell culture medium developed by inventors from Singapore, aimed at preparing stem cells from differentiated cells or maintaining stem cells in an undifferentiated state. The medium includes specific components such as ABL and SRC dual kinase inhibitors, mitogenic factors, and WNT signaling pathway activators. This invention addresses the need for new cell culture protocols to obtain sufficient quantities of cells and stem cells for cellular therapies and in vitro studies, particularly focusing on gut lineage cells and pancreatic beta cells. [Extracted from the article]

A patent application by inventor Aya OGASAWARA, assigned to Fujifilm Corporation, details an image processing apparatus, method, and program for generating medical images of lesions in their early stages. The technology involves machine learning to improve lesion detection accuracy and is particularly focused on the pancreas. By receiving relationship information between partial regions in the target organ, the apparatus can create medical images with indirect findings related to lesion occurrence. This innovation aims to enhance early detection capabilities in medical imaging. [Extracted from the article]

Oncolytics Biotech Inc., a clinical-stage company specializing in immunotherapy for oncology, has announced key progress and upcoming studies for breast and pancreatic cancer treatments. The company's recent BRACELET-1 study showed that pelareorep combination therapy could improve outcomes in HR+/HER2- breast cancer patients. They plan to submit a pelareorep + paclitaxel combination therapy breast cancer trial to the FDA in early 2025. Additionally, Oncolytics Biotech is continuing to develop pelareorep in gastrointestinal cancers and is evaluating its efficacy in anal cancer and pancreatic cancer. [Extracted from the article]

A patent has been issued to Arctx Medical Inc. for an apparatus and method designed to cool and/or heat organs, particularly focusing on the pancreas. The invention aims to provide localized hypothermia treatment for pancreatitis and other conditions, offering potential benefits for patients, physicians, and healthcare systems. The patent outlines various devices and methods for inducing localized hypothermia, including the use of catheters and heat exchange processes both inside and outside the patient's body. [Extracted from the article]

Orizuru Therapeutics Inc. has submitted a patent application for a "Maturation Agent" that aims to induce the differentiation of pluripotent stem cells into insulin-producing cells. The method involves culturing pancreatic endocrine progenitor cells or cells at a later stage of differentiation in a medium containing a compound with tubulin polymerization-promoting or tubulin depolymerization-inhibiting activity. This method can reduce unintended cells in the resulting insulin-producing cell population, which is important for safety in diabetes mellitus treatment. The patent application provides detailed claims and descriptions of the invention. [Extracted from the article]

A patent application titled "Analyte Detection Device With Multilayer Adhesive Tape" has been published online by the US Patent and Trademark Office. The patent application, filed by inventor Cuijun Yang, describes an analyte detection device with multiple layers of adhesive tape. The device is designed to improve the working time and user experience of adhesive tape used in continuous glucose monitoring for diabetic patients. The invention includes features such as annular structure adhesive tape, tearing parts for easy removal, and protective films to prevent adhesion between layers. The assignee for this patent application is Medtrum Technologies Inc. from Shanghai, China. [Extracted from the article]

A patent application by inventor Cuijun Yang has been made available online for an interlocking drug infusion device and artificial pancreas. The device aims to prevent over-infusion of insulin in diabetic patients by using a program module and position detection module to provide driving instructions to the actuator. This interlock mechanism ensures that the device continues to function even in the event of electronic component failure, reducing the risk of hypoglycemia or coma. The invention also includes an elastic member to reset the driving unit and various arrangements for the position detection element. The patent application was filed by Medtrum Technologies Inc. and is part of ongoing efforts to improve diabetes management technology. [Extracted from the article]

Toray Industries Inc. has been issued a patent for a kit or device that can detect early stage pancreatic cancer or pancreatic cancer precursor lesions. Pancreatic cancer is difficult to detect early and has a poor prognosis. The current tumor markers are not effective for early detection. This invention focuses on measuring the expression level of hsa-miR-1343-5p in blood samples to detect pancreatic cancer. If the level is increased compared to a control, it indicates the presence of pancreatic cancer, and treatment or diagnostic procedures can be initiated. The method involves measuring the expression level of hsa-miR-1343-5p in a sample from a human subject and comparing it to known samples from pancreatic cancer patients and healthy subjects to discriminate between the two. This method can be used for early detection of pancreatic cancer. [Extracted from the article]

A new study published in the Acta Materia Medica journal explores the potential of brusatol (BRT) as an adjuvant therapy for pancreatic ductal adenocarcinoma carcinoma (PDAC). Chemoresistance to gemcitabine (Gem) is a major challenge in PDAC treatment, and the transcription factor Nrf2 has been implicated in this resistance. The study found that BRT effectively inhibited PDAC cell proliferation and enhanced chemosensitivity to Gem by suppressing Nrf2 signaling. These findings suggest that BRT may have the potential to enhance the efficacy of Gem in PDAC treatment. [Extracted from the article]

A recent study from the Russian Academy of Sciences explores the features of beta cell differentiation in the development of type 2 diabetes mellitus. The research found that type 2 diabetes is characterized by an inflammatory reaction in the pancreas, which affects the structure and function of the pancreatic islets. The study used biochemical and histological methods to examine the changes in cell differentiation and found that reducing the inflammatory response led to an increase in the number of insulin-synthesizing cells and a decrease in cells synthesizing glucagon. The researchers suggest that targeted interventions in the cell microenvironment could be a new approach to treating type 2 diabetes. [Extracted from the article]

A recent research report from the Lawson Health Research Institute in London, Canada, highlights the importance of fetal and neonatal development in determining future metabolic health and disease risk. The study emphasizes that both maternal undernutrition and overnutrition can lead to abnormal fetal organ development, which can result in obesity, Type 2 diabetes, and cardiovascular diseases later in life. The report also discusses the role of maternal-placental-fetal metabolic axis and its impact on pancreatic function, insulin sensitivity, and gene expression. While interventions in obese mothers or those with gestational diabetes can improve metabolic control, their effectiveness in changing the adverse metabolic trajectory in the child is still uncertain. [Extracted from the article]

A new report from AntiCancer Inc. presents fresh data on pancreatic cancer, a disease with a poor prognosis and low survival rate. The study evaluated the efficacy of combining methionine restriction with first-line chemotherapy in a patient with stage IV metastatic pancreatic cancer. The patient experienced a 40% reduction in tumor size and an 86% decrease in the CA19-9 blood marker after five months of combination therapy. The research concludes that methionine restriction, along with a low-methionine diet and oral recombinant methioninase, was highly effective in treating inoperable stage IV pancreatic cancer. [Extracted from the article]

A patent has been issued to Amgen Inc. for substituted piperazines as KRAS G12C inhibitors. KRAS gene mutations are common in various types of cancer, including pancreatic cancer, lung adenocarcinoma, and colorectal cancer. The compounds described in the patent can be used to inhibit KRAS G12C activity and treat cancer. The patent provides information on the chemical structures of the compounds and their pharmaceutical formulations. This patent may be of interest to researchers studying cancer treatments and biopharmaceutical companies in the healthcare industry. [Extracted from the article]

A patent application by Vertex Pharmaceuticals Incorporated has been made available online, describing a composition for generating stem cell-derived pancreatic beta cells. This composition, which includes a water-soluble synthetic polymer and precursor cells, has the potential to be used in the treatment of diabetes by providing an unlimited supply of human beta cells for transplantation. The patent application also mentions the inclusion of growth factors and inhibitors to enhance the differentiation process. More information and detailed claims can be found in the patent application, accessible through the provided URL. [Extracted from the article]

A patent has been issued to Incyte Corporation for imidazole and triazole KRAS inhibitors. Ras proteins are small GTPases that regulate intracellular signaling pathways responsible for cell growth and differentiation. Mutations in the KRAS gene are prevalent in various cancers, including pancreatic, colorectal, and lung cancer. The patent describes compounds and pharmaceutical compositions that inhibit KRAS activity and can be used in the treatment of diseases characterized by a KRAS mutation. The full patent can be accessed for further information. [Extracted from the article]

A patent application has been submitted for an analyte detection device with circuit board and shell integration. The device is designed to monitor glucose levels in diabetics and send data to a remote device in real time. The invention aims to create a smaller and more integrated device by arranging the electronic circuit on the shell of the transmitter module, reducing the space occupied by the circuit board. The device also includes a battery located in the bottom case to provide electric energy for the transmitter module. The patent application was filed by Yang, Cuijun and assigned to Medtrum Technologies Inc. [Extracted from the article]

A patent application has been submitted for a skin patch drug infusion device by inventor Yang, Cuijun. The device aims to improve the accuracy of drug infusion for diabetic patients. It includes a control mechanism module and an infusion mechanism module that are electrically connected to each other. The device also features blocking walls to control the rotation amplitude of the driving member and allow for flexible infusion modes. The invention aims to provide a more accurate and customizable method of drug delivery for diabetes management. [Extracted from the article]

The article reports on a patent for engineered amylase variants filed by the inventors Chinping Chng, Da Duan, Ravi David Garcia, and Harvinder Chagger Maniar on September 6, 2023 and published online on August 27, 2024. The patent was assigned to Codexis Inc. Also mentioned are background information on pancreatic enzyme replacement therapy and polynucleotides encoding the engineered amylase polypeptides, as well as methods for making the engineered polynucleotides and amylase polypeptides.

A patent has been issued to Curis Inc. for conjoint therapies for immunomodulation. The patent describes methods of modulating the immune response in a subject by using inhibitors of the VISTA pathway and the TIM-3 pathway. These pathways are immune checkpoints that suppress T-cell activation and limit T-cell function and survival. The invention aims to provide more effective and durable therapies for cancer patients who become unresponsive to therapies targeting PD-1, PD-L1, or PD-L2. The patent includes specific compounds and methods for treating various types of cancer, including small cell lung cancer, multiple myeloma, bladder carcinoma, ovarian carcinoma, and pancreatic cancer. [Extracted from the article]

A patent application by inventors Michael Conway and Tudor Fulga, assigned to Vertex Pharmaceuticals Incorporated, has been made available online. The application discusses the use of hypoimmune cells, which are produced from genetically modified stem cells, for cell-based therapies. These cells have disruptions in the 3'-untranslated region (3'-UTR) of alleles encoding immunosuppressors, reducing the binding of RNA-binding proteins and microRNAs. The patent application also describes methods of producing these cells and their potential use in treating diseases like diabetes and cancer. The invention includes both embryonic and pluripotent stem cells with reduced expression of MHC-I and MHC-II human leukocyte antigens. [Extracted from the article]

A patent has been issued for an endoscope cleaning instrument by Olympus Corporation. The instrument is detachably attachable to the distal end portion of an endoscope and is designed to clean and disinfect the uneven surfaces of the endoscope, including the observation window, illumination window, raising base, and channel opening section. The cleaning instrument includes a covering member with a tubular shape that can cover the outer circumferential surface of the bending section of the endoscope. It also has a fluid supply port for supplying cleaning and disinfection liquid. The patent provides detailed descriptions and claims for the design and features of the cleaning instrument. [Extracted from the article]

Immunotherapy has become a standard treatment for many types of cancer, but it is not effective for most pancreatic ductal adenocarcinoma (PDAC) patients. However, researchers at Cold Spring Harbor Laboratory have discovered that a common chemotherapy supplement called folinic acid weakens PDAC's defenses in mice. This leads to a more effective immune response, slower tumor growth, and longer survival. The researchers are now working to develop potential drugs that target PDAC's defensive proteins, which could make immunotherapy a viable option for all PDAC patients in the future. [Extracted from the article]

Researchers from Boston Scientific Scimed Inc. have submitted a patent application for a "Flow Control Stent" to the United States Patent and Trademark Office. The medical device is designed to establish fluid communication between two body lumens in a controlled manner for a limited period of time. It includes an elongate tubular body with a constricted portion that can move between different diameter configurations in response to applied force. The device can be used for various medical conditions that require periodic or intermittent drainage and access to a body lumen or organ. [Extracted from the article]

The article focuses on a U.S. patent application filed by Fractyl Health Inc., detailing a method for treating metabolic and pancreatic diseases. It explains that the patent describes a device and technique for precise delivery of treatment agents, such as gene therapy materials, to specific sites in the pancreas via endoscopic injection. It states that the method aims to improve treatment efficiency while minimizing distribution to non-target tissues and reducing patient risk.

A patent application has been submitted to the US Patent and Trademark Office for a method of generating stem cell-derived beta cells for the treatment of diabetes. The application, assigned to Vertex Pharmaceuticals Incorporated, describes a composition that includes differentiated beta cells, as well as other cell types, that secrete insulin, glucagon, and somatostatin. The invention aims to provide a limitless supply of human beta cells for transplantation, potentially benefiting numerous patients. The patent application provides detailed claims and methods for generating these cell populations. For more information, refer to the full patent application. [Extracted from the article]

A patent has been issued to Gensun Biopharma Inc. for trispecific T cell engagers, a type of treatment for cancer. The patent describes the use of antibodies to target specific proteins associated with cancer cells, such as Delta-like ligand 3 (DLL3), Mucin 17 (MUC17), and Claudin-18 (CLDN18). These antibodies can be used alone or in combination to activate the immune system and kill tumor cells. The invention offers a potential improvement over conventional cancer treatments, which can have limited effectiveness and harmful side effects. [Extracted from the article]

A recent study conducted at Cold Spring Harbor Laboratory in New York has found that intratumoral accumulation of natural killer T (NKT) cells is crucial for establishing an immunologically active tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDA). The presence of NKT cells facilitates the production of type I interferon (IFN), which initiates an antitumor adaptive immune response and promotes the infiltration of various immune cells into the tumor. The researchers also discovered that administration of folinic acid to mice with PDA increased NKT cell levels in the TME and improved their response to anti-PD-1 antibody treatment. This study suggests that NKT cells could be potential targets for immunotherapy in pancreatic cancer. [Extracted from the article]

A patent application has been published for a method of treating beta-cell failure or dysfunction, which is associated with diabetes. The method involves administering a cyclic dipeptide called cyclo (His-Pro) (CHP) to a patient, potentially in combination with zinc and other antidiabetic drugs. The inventors believe that CHP has therapeutic effects on glucose metabolism and insulin secretion, but more research is needed. Another patent application discusses a new drug being developed by Novmetapharma Co. Ltd. that targets glucose metabolism disorders, specifically hyperglycemia and type 2 diabetes. The drug is based on the hormones glucagon and proinsulin, and it has the potential to improve glucose metabolism and treat these conditions. This research has implications for pancreas research and the development of new drugs and therapies for obesity and diabetes. [Extracted from the article]

This article discusses a patent application for an analyte detection device with circuit board and shell integration. The device is designed to monitor glucose levels in diabetics and send data to a remote device in real time. The invention aims to create a smaller and more integrated device by arranging the electronic circuit on the shell of the transmitter module, eliminating the need for a separate circuit board. The device also includes a battery for power and features a design that maximizes space utilization. The patent application was filed by Yang, Cuijun and is assigned to Medtrum Technologies Inc. [Extracted from the article]

A patent application titled "Battery Shell Integrated Analyte Detection Device" has been published online by the US Patent and Trademark Office. The patent application, filed by inventor Cuijun Yang, describes a device that integrates a battery shell with an analyte detection device. The device is designed to monitor glucose levels in diabetics and can transmit data to external equipment. The integration of the battery shell allows for a smaller device size and increased battery capacity. The invention aims to improve the miniaturization and performance of analyte detection devices for diabetes management. The assignee for this patent application is Medtrum Technologies Inc. [Extracted from the article]

A patent has been issued for neuromodulation and associated systems and methods for the management of pain. The patent focuses on treating chronic pain associated with conditions such as hepatobiliary diseases, pancreatic conditions, and reproductive/genital organ conditions. The technology involves modulating nerve structures associated with abdominal viscera and reproductive organs to reduce perceived pain. The patent describes various embodiments and treatment modalities, including electrically-induced, thermally-induced, and chemically-induced approaches. The system includes a processing device to determine changes in pain parameters and control the delivery of neuromodulation therapy. The patent was filed by inventors from Menlo Park, CA, Litchfield Park, AZ, and St. Augustine, FL, and is assigned to Medtronic Ireland Manufacturing Unlimited Company. [Extracted from the article]

A new study on pancreatic cancer has found that the tumor microenvironment in pancreatic cancer secretes cytokines, including interleukin (IL)-1, which exerts immunosuppressive activities. Researchers have developed sphingomyelin nanosystems (SNs) loaded with anakinra (ANK), a recombinant IL-1 receptor antagonist, to inhibit pro-tumor inflammation in pancreatic cancer. The study found that ANK-SNs were effective in inhibiting the release of pro-tumor cytokines and IL-17 secretion by Th17 cells, potentially reducing the effective dose of the drug and its toxic effects. This research provides insights into potential therapeutic strategies for pancreatic cancer. [Extracted from the article]

A patent has been issued to Tango Therapeutics Inc. for HDAC inhibitors and their therapeutic use in treating various diseases, including cancers. HDAC inhibitors are a class of proteins that have been implicated in diseases, and selective inhibitors are needed to minimize adverse effects. The patent includes compounds and compositions for treating non-small cell lung cancer, endometrial cancer, pancreatic cancer, cervical cancer, and cancer of unknown primary. The methods involve administering the compounds with or without an anti PD-1 antibody or pembrolizumab. This information is based on a patent filed by the inventors Guerin, Maxwell, and Wu. [Extracted from the article]

A recent study conducted by researchers at Evidera Inc. aimed to develop a standardized patient-reported outcome (PRO) questionnaire to assess symptoms in patients diagnosed with exocrine pancreatic insufficiency (EPI). The study involved concept elicitation interviews and cognitive interviews with US patients diagnosed with EPI. The results indicated that the developed questionnaire, called the EPI Symptom Questionnaire (EPI-SQ), demonstrated content validity in measuring EPI symptom severity in US patient populations. This research provides valuable insights into the symptom experience of patients with EPI and offers a useful tool for assessing and managing the condition. [Extracted from the article]

A patent application has been submitted by ViaCyte Inc. for a cellular therapy and means and methods for holding, transferring, sizing, marking, and deploying a cell encapsulation implantable device for the treatment of diabetes mellitus. The invention aims to provide a renewable cell source and an encapsulation source that provides protection against host immunity, minimizing the need for long-term immune-suppressive drugs. The patent application describes a case for holding an implantable device, which includes a detachably connected cover body and base body with openings to allow the passage of biologically active materials. The inventors also provide various embodiments and claims related to the case design and materials used. [Extracted from the article]

A patent has been issued for an endoscopic cryoablation catheter developed by CPSI Holdings LLC. The device aims to provide a more effective and less invasive treatment option for pancreatic cancer. Current therapeutic options for unresectable pancreatic cancer, such as radiofrequency ablation, have limitations and risks. The cryoablation catheter is designed to overcome these limitations by providing better cooling power and minimizing damage to surrounding tissues. The device can be used in conjunction with endoscopic ultrasound for real-time imaging and guidance during the procedure. [Extracted from the article]

A patent application has been submitted for a highly integrated analyte detection device by Medtrum Technologies Inc. The device aims to improve the monitoring of blood glucose levels in diabetics. The invention integrates a battery cavity into the transmitter module, allowing for a smaller battery volume and larger capacity. The device also includes a sensor, transmitter, and electrical contact for transmitting analyte parameter information to external equipment. The integration of the battery, transmitter shell, and circuit board allows for greater miniaturization and improved user experience. [Extracted from the article]

A patent application titled "Il-13ralpha2 Targeted Immunotoxins And Methods Of Use" has been published online by the United States Patent and Trademark Office. The patent application describes immunotoxins that specifically bind to IL-13Ra2, a protein associated with certain cancers. These immunotoxins are linked to cytotoxic proteins and can be used to treat IL-13Ra2-expressing tumors or cancers, as well as reduce perineural invasion and associated pain. The patent application also includes information on nucleic acids, vectors, host cells, and methods of producing and administering the immunotoxins. [Extracted from the article]

A patent application titled "Battery Shell Integrated Analyte Detection Device" has been published online by the US Patent and Trademark Office. The patent application, filed by inventor Cuijun Yang, describes a device that integrates a battery shell with an analyte detection device. The device is designed to monitor glucose levels in diabetics and transmit the data to external equipment. The integration of the battery shell allows for a smaller device size and increased battery capacity. The patent application provides detailed information about the design and components of the device. The assignee for this patent application is Medtrum Technologies Inc. from Shanghai, China. [Extracted from the article]

A patent application titled "Methods For Detection Of Donor-Derived Cell-Free DNA In Transplant Recipients Of Multiple Organs" has been published online by Natera Inc. The inventors propose a non-invasive transplantation rejection test for transplant recipients of multiple organs that is more sensitive and specific than conventional biopsy-based tests. The method involves extracting cell-free DNA from a blood, plasma, serum, or urine sample of the recipient, performing targeted amplification and sequencing of the DNA, and determining whether the amount of donor-derived cell-free DNA exceeds a cutoff threshold indicating transplant rejection or graft injury. The patent application provides detailed claims and methods for performing the test. [Extracted from the article]

Splenic venous hypertension (SVH), also known as left-sided portal hypertension, is a rare condition characterized by upper gastrointestinal bleeding without liver disease. SVH occurs when there is increased pressure in the splenic vein, leading to blood draining through the short gastric veins to the stomach and the formation of gastric varices. The condition can be caused by compression, stenosis, inflammation, thrombosis, or surgical interventions that decrease splenic venous flow. Diagnosis involves clinical suspicion and imaging studies, and treatment options include surgical and endoscopic approaches, splenic artery embolization, and pharmacological treatments. The prognosis depends on the underlying cause, with proper management leading to a favorable outcome. [Extracted from the article]